In our study, a differential analysis revealed that only in KIRC for CD36, and in ACC and LGG for MYD88, could we significantly stratify patients into high and low expression groups based on median expression levels, which corresponded to distinct survival outcomes. The gene discussed is MYD88; the disease is adrenal cortex carcinoma.